Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
Tibotec BVBA is developing the diarylpyrimidine rilpivirine, a second-generation non-nucleoside reverse transcriptase inhibitor for the potential treatment of HIV infection. A phase III trial of rilpivirine in HIV-infected, treatment-naive indivuduals is underway and is to be completed by August 2010.